Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 May 26;322(7297):1271-4.
doi: 10.1136/bmj.322.7297.1271.

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

P J Poole  1 , P N Black
Affiliations

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

P J Poole et al. BMJ. .

Abstract

Objective: To assess the effects of oral mucolytics in adults with stable chronic bronchitis and chronic obstructive pulmonary disease.

Design: Systematic review of randomised controlled trials that compared at least two months of regular oral mucolytic drugs with placebo.

Studies: Twenty three randomised controlled trials in outpatients in Europe and United States.

Main outcome measures: Exacerbations, days of illness, lung function, adverse events.

Results: Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean difference -0.07 per month, 95% confidence interval -0.08 to -0.05, P<0.0001). Based on the annualised rate of exacerbations in the control subjects of 2.7 a year, this is a 29% reduction. The number needed to treat for one subject to have no exacerbation in the study period would be 6. Days of illness also fell (weighted mean difference -0.56, -0.77 to -0.35, P<0.0001). The number of subjects who had no exacerbations in the study period was greater in the mucolytic group (odds ratio 2.22, 95% confidence interval 1.93 to 2.54, P<0.0001). There was no difference in lung function or in adverse events reported between treatments.

Conclusions: In chronic bronchitis and chronic obstructive pulmonary disease, treatment with mucolytics is associated with a reduction in acute exacerbations and days of illness. As these drugs have to be taken long term, they could be most useful in patients who have repeated, prolonged, or severe exacerbations of chronic obstructive pulmonary disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (SD) number of exacerbations per subject per month, weighted mean difference, and 95% confidence intervals
Figure 2
Figure 2
Lung function at end of study period
See this image and copyright information in PMC

Comment in

References

    1. Redline S. Epidemiology of COPD. In: Cherniack N, editor. Chronic obstructive pulmonary disease. Philadelphia: Saunders; 1991.
    1. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema: an eight year study of early chronic lung disease in working men in London. Oxford: Oxford University Press; 1976.
    1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jefferies DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422. - PubMed
    1. Feinleib M, Rosenberg HM, Collins JG, Delozier JE, Pokras R, Chevarley FM. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis. 1989;140:S9–18. - PubMed
    1. Del Donno M, Olivieri D. Mucoactive drugs in the management of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 1998;53:714–719. - PubMed

Publication types

MeSH terms